• Aurora A Overexpression in Retinoblastoma

  2026-09-11

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a clinically relevant feature of human retinoblastoma and links it to histopathologic high-risk factors. By combining patient-tissue profiling with genetic depletion, pharmacologic inhibition, patient-derived material, and xenograft models, the work supports AURKA as a therapeutic vulnerability while highlighting its functional relationship with MYCN.

• Fluconazole Workflows for Candida Resistance

  2026-09-10

  Build reproducible Fluconazole assays for ergosterol disruption, susceptibility profiling, and Candida infection research. This guide connects practical stock handling with resistant-isolate comparisons and delayed-treatment study design.

• VX-745 in Reliable p38α MAPK Assays

  2026-09-10

  This scenario-based guide explains how VX-745, SKU A8686, can support reproducible studies of p38α MAPK signaling, cytokine secretion, proliferation, and cytotoxicity. It links biochemical potency with practical solvent handling, assay controls, interpretation, and evidence-aware product selection.

• SAG: Smoothened Receptor Agonist Workflows

  2026-09-09

  SAG provides a direct, controllable route to Smoothened activation for pathway assays, mechanistic rescue experiments, neurobiology models, and developmental studies. This guide connects product handling with the reference study’s ligand-versus-receptor assay logic, practical controls, and troubleshooting decisions.

• Verbascoside for PKC/NF-κB Assay Design

  2026-09-09

  Verbascoside provides a reversible small-molecule approach for dissecting PKC/NF-κB signaling in RANKL-driven osteoclastogenesis and related bone-cell models. This guide connects concentration planning, pathway readouts, and troubleshooting with a recent study of the TLR4/NF-κB/FGF21 axis in glucocorticoid-induced osteonecrosis.

• iPSC-Based Clinical Trial Selection for Ultrarare Disease

  2026-09-08

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like disorder caused by poorly characterized ECHS1 variants. The study shows how disease-relevant cellular models can connect genotype, functional drug response, and later clinical decision-making while reducing reliance on trial-and-error treatment.

• CBD in Orofacial Inflammatory Pain: Mechanisms

  2026-09-08

  This 2026 study shows that cannabidiol reduces both nociceptive and pain-related affective abnormalities in mouse models of orofacial and chronic inflammatory pain. Its main contribution is a multilevel mechanism linking peripheral FAAH and CB2 signaling with central CB1-dependent endocannabinoid activity and serotonin dynamics in the central amygdala.

• Flumequine in Reliable Topoisomerase II Assays

  2026-09-07

  Flumequine (SKU B2292) offers a defined, DMSO-soluble research compound for DNA topoisomerase II inhibition, DNA replication research, and carefully interpreted cell-response studies. This scenario-based guide connects product specifications with practical assay design, viability-metric selection, and reproducible data interpretation.

• Biotin (Vitamin B7) for Precision Assays

  2026-09-07

  Biotin (Vitamin B7) connects carboxylase reconstitution, affinity-based detection, and carefully controlled protein biotinylation workflows. Its value in motor-protein studies is analytical rather than regulatory: biotin enables selective capture and readout while BicD and MAP7 are tested as separate modulators of kinesin-1 activity.

• SARS-CoV-2 Nucleocapsid Rewires GADD34 Immunity

  2026-09-05

  The reference study identifies an atypical stress granule-like mechanism through which SARS-CoV-2 nucleocapsid protein sequesters GADD34 mRNA with G3BP1, weakening IRF3 nuclear localization and type I interferon production. Its main contribution is to connect viral condensate formation with post-transcriptional suppression of an innate immune regulator, providing a mechanistic framework for studying SARS-CoV-2 immune evasion.

• Z-YVAD-FMK in HOXC8–Caspase-1 Cancer Research

  2026-09-04

  Explore how Z-YVAD-FMK, a cell-permeable caspase-1 inhibitor, can convert HOXC8-driven lung cancer findings into rigorous pyroptosis and apoptosis assay decisions. This article emphasizes causal interpretation, pathway controls, and experimental limitations rather than routine inhibitor handling alone.

• Verapamil HCl Targets Txnip in Osteoporosis

  2026-09-04

  The reference study identifies Txnip as a potential molecular link between verapamil exposure and bone remodeling, combining human genetic association data, cell-based assays, and an ovariectomized mouse model. Its findings suggest that verapamil can reduce abnormal bone turnover through ChREBP-dependent signaling in osteoclasts and osteoblasts, although clinical efficacy and calcium-channel dependence remain to be established.

• VX-765: Caspase-1 Workflows and Troubleshooting

  2026-09-03

  VX-765 enables targeted investigation of caspase-1-dependent cytokine processing and pyroptosis, while its prodrug conversion adds an important experimental variable. This workflow-focused guide covers assay design, macrophage applications, disease-model interpretation, and troubleshooting for more defensible inflammation data.

• SLC2A5 and Fructose Metabolism in PCNSL

  2026-09-03

  This 2026 Advanced Science study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic primary central nervous system lymphoma supports SLC2A5-mediated fructose metabolism in malignant cells and tumor-supportive macrophages. Genetic and pharmacologic SLC2A5 inhibition reduced lymphoma growth in functional models, identifying a metabolic vulnerability while highlighting the need for further clinical validation.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-09-02

  The reference study shows that phillygenin protects against diabetic nephropathy in high-glucose podocytes and db/db mice by suppressing TLR4/MyD88/NF-κB-associated inflammation while supporting PI3K/AKT/GSK3β signaling. Its combined cellular, transcriptomic, biochemical, and animal-model design provides a useful preclinical framework for connecting podocyte injury, apoptosis, inflammation, and albuminuria.

8110 records 6/541 page Previous Next First page 上5页 678910 下5页 Last page